Septerna (NASDAQ:SEPN) Price Target Raised to $61.00

Septerna (NASDAQ:SEPN) had its price target raised by Wells Fargo & Company from $50.00 to $61.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

SEPN has been the topic of a number of other research reports. Raymond James Financial restated a “strong-buy” rating and issued a $49.00 price target on shares of Septerna in a research note on Tuesday, August 11th. Guggenheim lifted their price objective on shares of Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Thursday, October 15th. Stifel Nicolaus set a $49.00 price objective on shares of Septerna in a research report on Tuesday, August 11th. Finally, HC Wainwright raised their target price on shares of Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.22.

Septerna Stock Performance

Septerna stock traded up $1.50 during midday trading on Wednesday, reaching $48.85. 384,548 shares of the company’s stock were exchanged, compared to its average volume of 378,831. Septerna has a 52 week low of $17.55 and a 52 week high of $51.10. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -90.46 and a beta of 2.20. The stock’s 50-day simple moving average is $39.52 and its 200 day simple moving average is $32.59.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.14. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%. The firm had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. Research analysts forecast that Septerna will post -1.41 earnings per share for the current year.

Insider Activity at Septerna

In other Septerna news, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $37.41, for a total value of $149,640.00. Following the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $6,517,158.69. This represents a 2.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Daniel D. Long sold 3,333 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total transaction of $126,087.39. Following the completion of the sale, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,647,265.96. This represents a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 32,333 shares of company stock valued at $1,375,727. 5.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Sterling Capital Management LLC boosted its stake in shares of Septerna by 215.0% in the third quarter. Sterling Capital Management LLC now owns 630 shares of the company’s stock valued at $25,000 after buying an additional 430 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Septerna during the 3rd quarter worth $93,000. Covestor Ltd increased its stake in Septerna by 19.0% during the 3rd quarter. Covestor Ltd now owns 2,526 shares of the company’s stock worth $98,000 after acquiring an additional 403 shares during the period. The Manufacturers Life Insurance Company bought a new position in Septerna during the 2nd quarter worth $211,000. Finally, Canada Pension Plan Investment Board acquired a new position in Septerna in the 2nd quarter valued at $298,000.

Septerna Company Profile

Septerna, Inc is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in a wide range of biological processes and represent an important source of potential drug targets.

The company’s research is powered by its Native State platform, which is designed to study GPCRs in their natural biological configuration and support the discovery of selective small-molecule compounds.